Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 1.00 |
| ▸ | CHAT | P28329 | 1/20 | 1.00 |
| ▸ | TTR | P02766 | 2/20 | 0.67 |
| ▸ | FABP4 | P15090 | 1/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.67 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | NSD2 | O96028 | 2/20 | 0.51 |
| ▸ | CASP6 | P55212 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261938 | 1.00 | SNCA (1.00) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL29382721 | 1.00 | SNCA (1.00) | SNCACHATTTRFABP4CCNA2 | |
| Potassium SCHEMBL1082234 | 0.99 | SNCA (0.97) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL20574382 | 0.99 | SNCA (0.97) | SNCACHATTTRFABP4CCNA2 | |
| Pyrophosphoric Acid SCHEMBL31296093 | 0.90 | SNCA (0.81) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL30449729 | 0.86 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL11508403 | 0.86 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| SCHEMBL12177963 | 0.86 | SNCA (0.75) | SNCACHATTTRFABP4CCNA2 | |
| Potassium Ion SCHEMBL1082232 | 0.84 | SNCA (0.72) | SNCACHATTTRFABP4CCNA2 | |
| Potassium Ion SCHEMBL29360751 | 0.84 | SNCA (0.72) | SNCACHATTTRFABP4CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12174161-B2 | Methods of measuring hydrophobicity of chromatographic resins | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-24 | — | — | US | claimed |
| US-20220042954-A1 | METHODS OF MEASURING HYDROPHOBICITY OF CHROMATOGRAPHIC RESINS | BRISTOL-MYERS SQUIBB COMPANY | 2022-02-10 | — | — | US | claimed |
| EP-1578773-A3 | METHODS AND PRODUCTS BASED ON OLIGOMERIZATION OF STRESS PROTEINS | Antigenics Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050221395-A1 | Methods and products based on oligomerization of stress proteins | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-10-06 | — | — | US | claimed |
| EP-1578773-A2 | METHODS AND PRODUCTS BASED ON OLIGOMERIZATION OF STRESS PROTEINS | Antigenics Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2003072595-A2 | METHODS AND PRODUCTS BASED ON OLIGOMERIZATION OF STRESS PROTEINS | ANTIGENICS INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-05-12 | — | — | US | disclosed |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-12540947-B2 | High throughput, fluorescence-based estimation of monoclonal antibody aggregation with disodium 3,3′-{[(E)-1,2-diphenyl-1,2-ethenediyl]bis(4,1-phenyleneoxy)}di (1-propanesulfonate) dye for superior sensitivity and specificity | AGILENT TECHNOLOGIES, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4072671-B1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | CENTESSA PHARMACEUTICALS UK LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-07-22 | — | — | US | disclosed |
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-05-06 | — | — | US | disclosed |
| US-12286402-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | CENTESSA PHARMACEUTICALS (UK) LIMITED (GB) | 2025-04-29 | — | — | US | disclosed |
| WO-2005077940-A1 | DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF AND THE SYNTHESIS OF DEHYDROPHENYLAHISTINS AND ANALOGS THEREOF | NEREUS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050123563-A1 | Lipoparticles comprising proteins, methods of making, and using the same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050079526-A1 | Methods and apparatuses for characterizing refolding and aggregation of biological molecules | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2005-04-14 | — | — | US | disclosed |
| US-20040072356-A1 | Methods and apparatuses for characterizing stability of biological molecules | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2004-04-15 | — | — | US | disclosed |
| WO-2003072595-A2 | METHODS AND PRODUCTS BASED ON OLIGOMERIZATION OF STRESS PROTEINS | ANTIGENICS INC. (US) | 2003-09-04 | — | — | WO | disclosed |
| WO-2003071269-A2 | METHODS AND APPARATUSES FOR CHARACTERIZING STABILITY OF BIOLOGICAL MOLECULES | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-08-28 | — | — | WO | disclosed |
| US-20030125234-A1 | Alteration of protein stability | KANSAS UNIVERSITY OF | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12291507-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINH1 | SNCA 668/4885CHAT 1578/4885TTR 209/4885 |
| US-12611402-B2 | Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINE1 | SNCA 866/4885CHAT 1637/4885TTR 650/4885 |
| US-12624008-B2 | 4-((6-oxopyrimidin-1(6H)-yl)methyl)benzoic acid as an inducer of Z A1AT secretion for treating AATD | SERPINA2, SERPINB1, SERPINE1 | SNCA 866/4885CHAT 2614/4885TTR 523/4885 |
| US-12286402-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | SERPINA2, SERPINB1, SERPINH1 | SNCA 668/4885CHAT 1578/4885TTR 209/4885 |
| US-12365672-B2 | Compounds and their use for the treatment of alpha1-antitrypsin deficiency | SERPINA2, SERPINC1, SERPINB1 | SNCA 2099/4885CHAT 2028/4885TTR 133/4885 |
| US-12540947-B2 | High throughput, fluorescence-based estimation of monoclonal antibody aggregation with disodium 3,3′-{[(E)-1,2-diphenyl-1,2-ethenediyl]bis(4,1-phenyleneoxy)}di (1-propanesulfonate) dye for superior sensitivity and specificity | FCGR3B, FCGR2A, FCGR1A | SNCA 236/4885CHAT 2577/4885TTR 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.